Sermorelin & GHRP-6 Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Sermorelin & GHRP-6 Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic GHRH(1-29) fragment that stimulates pulsatile GH release via pituitary GHRHR; formerly FDA-approved as Geref (discontinued 2008). Research use only.

Sermorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Gs-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Binding stimulates adenylyl cyclase, increases intracellular cyclic AMP, activates protein kinase A, and promotes both synthesis and pulsatile exocytotic release of endogenous growth hormone. Because sermorelin acts upstream of the pituitary — causing the gland to release its own GH rather than supplying exogenous hormone — the resulting GH profile mirrors physiological pulsatility and remains subject to normal negative-feedback inhibition by somatostatin, which limits the degree of GH elevation achievable. Downstream GH signalling drives hepatic IGF-1 synthesis and the anabolic, lipolytic, and growth-promoting effects associated with the GH/IGF-1 axis.

Molar mass

3357.9 g/mol

Synthetic hexapeptide GHS-R1a agonist that triggers pulsatile GH release from pituitary somatotrophs; widely used in preclinical secretagogue research.

GHRP-6 is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by the endogenous orexigenic hormone ghrelin. Binding to GHS-R1a on pituitary somatotrophs couples through Gq/11 proteins to activate phospholipase C, generating IP3 and diacylglycerol, which mobilizes intracellular calcium stores and triggers exocytotic release of stored GH. Concurrently, GHRP-6 acts at hypothalamic GHS-R1a to suppress somatostatinergic tone and stimulate endogenous GHRH release, amplifying pituitary GH output through a dual central-pituitary mechanism. Secondary receptor interactions also lead to modest stimulation of cortisol and prolactin secretion, and prominent appetite stimulation via central ghrelin mimicry — effects that distinguish GHRP-6 from more selective secretagogues such as ipamorelin.

Molar mass

873.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Sinha DK et al. 2020 — Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol 9(Suppl 2):S149-S159. — COMPONENT-LEVEL narrative review covering sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin as a class; notes a paucity of clinical efficacy data. Not blend-level.
• Berlanga-Acosta J et al. 2017 — Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol 11. — COMPONENT-LEVEL (GHRP-6, GHRP family). Historical review of GHRP cytoprotective/cardioprotective mechanisms via GHS-R1a and CD36. Not blend-level.
• Ishida J et al. 2020 — Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications 3:25-37. — COMPONENT-LEVEL class review; notes sermorelin's 1990/1997 FDA approvals. Not blend-level.
• Sigalos JT et al. 2017 — Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health 11(6):1752-1757. — A retrospective chart review (n=14 compliant), NOT an RCT — observational only. Studies a 3-PEPTIDE combination (GHRP-2 + GHRP-6 + sermorelin) in men on testosterone therapy — an ADJACENT 3-part combination, not the exact 2-part Sermorelin+GHRP-6 pairing this overlay covers; cited here only as component/adjacent-combination context, never as evidence for this specific 2-part blend.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC)

Sermorelin: FDA-approved SC injection (0.2-0.3 mg once daily at bedtime) in adults/children under the withdrawn Geref label; peak plasma concentrations reached 5-20 min after SC administration of 2 mg to 12 normal volunteers. GHRP-6: SC GH-release characterized in humans at ~1-2 mcg/kg. Blend (sermorelin+GHRP-6, sometimes ±GHRP-2 in adjacent combinations): described as prescribed SC three times daily per SME interviews in an FDA-commissioned nomination background report — Layer B practitioner-interview evidence, not a controlled combination-PK trial.

Bioavailability: Sermorelin SC is the labeled, established route; peak 5-20 min post-SC dose (component-level, from the withdrawn Geref label). GHRP-6 SC produces reliable GH secretion; no isolated SC human dose-response trial exists for the two administered together as a unit.

Dominant route for both components individually and for the compounded blend as commercially sold. Sermorelin's (withdrawn) label specified SC only; GHRP-6 SC is well-characterized. Combination SC use is documented only via prescriber/SME interviews (Layer B), not controlled PK trials of the pairing.

Sermorelin (as Geref Diagnostic): approved by FDA as a diagnostic agent for ADULT growth hormone deficiency at 1 mcg/kg as a single IV injection in the early 1990s, per the background section of FDA's Egrifta (Tesamorelin) medical review (NDA 022505 is Tesamorelin's own application number, not sermorelin's — sermorelin/Geref itself was approved under NDA 20-443; independently confirmed against FDA's Drugs@FDA database this pass). Both Geref products (Diagnostic and the pediatric SC therapy) were later voluntarily withdrawn (2008 and 2006 respectively) and are no longer marketed. GHRP-6: Phase I human PK study in 9 healthy male volunteers after a single IV bolus of 100, 200, and 400 mcg/kg; elimination half-life ~2.5 h.

Bioavailability: IV provides 100% systemic delivery by definition. GHRP-6 IV half-life ~2.5 h (Cabrales et al. 2013). Sermorelin IV was used only for diagnostic testing, never as ongoing therapy, and both Geref products are discontinued.

IV is a characterized diagnostic/research route for each component separately (each confirmed against a primary FDA source this pass); no IV study of the sermorelin+GHRP-6 combination as a unit was identified.

Sermorelin: IM listed as an alternative injection route by compounding-pharmacy guidance only; not part of the FDA-approved (now-withdrawn) Geref label. No IM data located for GHRP-6.

Bioavailability: No published IM pharmacokinetic study for sermorelin or GHRP-6 was located; IM appears only in prescriber/compounding-pharmacy materials.

IM appears in community/compounding guidance for sermorelin but lacks primary PK evidence and is outside the FDA label; no IM data for the blend.

GHRP-6: oral GHRP-6 stimulated GH release in normal men at 300 mcg/kg (Hartman et al. 1992, PMID 1592884) and in children with short stature at 300 mcg/kg (Bellone et al. 1995, PMID 7581965 — a controlled clinical trial). Sermorelin has no oral formulation studied; the peptide is not orally active.

Bioavailability: GHRP-6's oral:IV dose ratio for a comparable GH response is ~300:1 (Hartman 1992) — commonly summarized as "~1% oral bioavailability" in secondary sources, though the underlying study measured response equivalence, not directly measured plasma AUC. Sermorelin is administered only by injection.

Oral route is studied for GHRP-6 alone (both PMIDs independently verified against PubMed this pass), never for the blend as a unit. Not a validated therapeutic oral regimen.

GHRP-6: intranasal bioavailability estimated 34.4-44.9% in conscious dogs (Nelson et al. 1991, Life Sci, PMID 2046459 — independently confirmed this pass). Intranasal GHRP-6 has produced significant nocturnal GH increases in human studies. No intranasal data located for sermorelin.

Bioavailability: GHRP-6 intranasal bioavailability ~34-45% in dogs; human intranasal GH-response data exist. No intranasal data for sermorelin or the blend.

Intranasal is a characterized alternative route for GHRP-6 (animal PK + human GH-response data) but not for sermorelin; the blend has no intranasal study.

GHRP-6: IP injection used in rodent organ-protection studies per research-grade supplier documentation; no primary published IP PK study located.

Bioavailability: No human IP data; IP is a preclinical/rodent research route only.

IP is documented only in animal-research contexts for GHRP-6, sourced from a vendor product page rather than peer-reviewed literature; no IP data for sermorelin or the blend.

GHRP-6: topical application described in wound-healing research contexts per vendor documentation; no primary published study located this pass.

Bioavailability: No human topical PK data located; topical is described only as a preclinical wound-healing research route.

Topical GHRP-6 is described only in vendor-sourced preclinical wound-healing framing; no topical data for sermorelin or the blend, and no unassisted passive human absorption is demonstrated anywhere.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $8.93 · median $9.54 · p75 $10.44 · 6 researched vendors

Legit, COA-backed band: $8.49–$10.66/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$85

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Component-level, not blend-level: Sermorelin batches report 98.77% (Iron Mountain Labz, in-house) to 99.21% (Panda Peptides, Janoshik-verified); GHRP-6 reports 99.12% (Iron Mountain Labz, in-house). No independent-lab aggregate survey specific to a combined Sermorelin+GHRP-6 blend product exists.

Independent labs cited for this compound

One recall identified, component-level only: Innoveix Pharmaceuticals, Inc. voluntarily recalled compounded Sermorelin/Ipamorelin 3 mg (July 9, 2021) due to lack of sterility assurance (acknowledged in FDA Warning Letter MARCS-CMS 624782, Jan 26, 2022). That product pairs sermorelin with Ipamorelin, not GHRP-6. No recall was found specifically for a Sermorelin + GHRP-6 co-formulated blend product.

Buyer red-flag checklist

• Sermorelin (Geref) was FDA-approved (NDA 20-443, 1997) but both the diagnostic (2008) and pediatric-therapy (2006) formulations were voluntarily withdrawn by the manufacturer for commercial reasons; retail/online products claiming to contain sermorelin today are outside that approved chain and are not FDA-reviewed for quality.
• GHRP-6 was never FDA-approved for any indication and sits on FDA Category 2 of the 503B interim bulks list (added Sept 29, 2023) due to potential immunogenicity from aggregation and peptide-related impurities — ineligible for routine compounding.
• Neither sermorelin nor GHRP-6 appears on the FDA 503A bulks list; compounded products using these substances are not eligible for section 503A exemptions (per the ImprimisRx warning letter).
• Multiple FDA Warning Letters (ImprimisRx 2019, Innoveix 2022, Xcel Research 2024) cite sermorelin- or GHRP-6-containing products as unapproved new drugs and/or produced under insanitary conditions — each names one component, never the blend as such.
• 'FOR RESEARCH USE ONLY' / 'NOT INTENDED FOR HUMAN USE' labeling is used by online vendors to market peptides FDA has determined are, based on website marketing claims, intended for human drug use (Xcel Research, 2024).
• Grey-market peptide imports of unapproved GH secretagogues may be subject to DWPE under the general unapproved-new-drug framework (Import Alert 66-41), though that alert does not name sermorelin or GHRP-6 individually.
• In-house vendor HPLC purity claims (e.g. Iron Mountain Labz) are not equivalent to independent third-party verification; only Janoshik-verified COAs provide independent confirmation for the batches checked here.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent-lab aggregate (Janoshik / MZ Biolabs / Finnrick) publishing underdosing/mislabeling prevalence data specifically for a Sermorelin + GHRP-6 blend was located. Individual vendor COAs report purity but not mass-quantitation underdosing rates for this blend.

• FDA Import Alert 66-71 ('Detention Without Physical Examination of Unapproved Human Growth Hormone (HGH)', independently confirmed via page metadata this pass) authorizes DWPE of unapproved HGH/somatropin drug products. Sermorelin and GHRP-6 are GH secretagogues/releasing peptides — not HGH itself — and are NOT named in this alert. A GH-secretagogue product imported as an unapproved new drug could instead face detention under the broader unapproved-new-drug framework (Import Alert 66-41), which likewise does not name these peptides individually.66-71
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

The Sermorelin & GHRP-6 blend itself is not named on the WADA Prohibited List (no product-level schedule exists for a named blend). Per component: sermorelin is a GHRH analog and GHRP-6 is a GH-releasing peptide/secretagogue — both classes are explicitly named under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times, in- and out-of-competition. USADA states a TUE for sermorelin is highly unlikely (not a first-line treatment; the commercial Geref product was discontinued in 2008). Direct re-verification of the WADA/USADA page content hit a Cloudflare bot-challenge this pass (not confirmed dead — the URL resolves, content just wasn't fetchable via automated request); the S2 classification of GHRH analogs/GH secretagogues is independently well-documented across anti-doping literature.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-reporting without lab confirmation.
• Vendor-affiliated or clinic-affiliated posters.
• Selection bias toward engaged peptide enthusiasts.
• Self-titrated dosing without medical oversight — not a protocol, and never asserted as one.
• Survivorship bias toward responders posting updates.
• Direct aggregate discourse naming this exact 2-peptide product specifically (vs the standalone compounds or adjacent 3-peptide GHRP-2/GHRP-6/sermorelin combinations) is thin; themes/concerns should be read as illustrative of the GH-secretagogue-stacking discourse broadly, not a dedicated high-volume thread population.

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only two-peptide blend of the GHRH analog Sermorelin and the growth hormone secretagogue GHRP-6. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet